Clinical Trials Logo

Clinical Trial Summary

Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02394015
Study type Observational
Source Grupo Español de Investigación en Cáncer de Ovario
Contact
Status Completed
Phase
Start date May 6, 2013
Completion date December 2017

See also
  Status Clinical Trial Phase
Completed NCT01899599 - PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer Phase 2
Active, not recruiting NCT01715168 - A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer Phase 1
Completed NCT01588964 - IPHC in Patients With Platinum-sensitive Recurrent Ovarian Cancer Phase 2
Completed NCT02026921 - A Phase II Study of Docetaxel and Carboplatin in Late Relapse of Ovarian Cancer Phase 2
Completed NCT02260544 - Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection Phase 1
Completed NCT01735071 - Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer Phase 2
Active, not recruiting NCT01611766 - Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)? Phase 3
Completed NCT02735928 - Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Applied to Platinum-Resistant Recurrence of Ovarian Tumor N/A
Completed NCT02014337 - Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors Phase 1
Active, not recruiting NCT01376752 - Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment Phase 3